Literature DB >> 30228206

Stromal Cell PD-L1 Inhibits CD8+ T-cell Antitumor Immune Responses and Promotes Colon Cancer.

Oliver Treacy1,2, Kevin Lynch2, Serika D Naicker2, Grace O'Malley1,2, Niamh A Leonard1,2, Paul Lohan2, Philip D Dunne3, Thomas Ritter2, Laurence J Egan1, Aideen E Ryan4,2.   

Abstract

Stromal cells of mesenchymal origin reside below the epithelial compartment and provide structural support in the intestine. These intestinal stromal cells interact with both the epithelial cell compartments, as well as infiltrating hematopoietic immune cells. The importance of these cells in regulating immune homeostasis during inflammation is well recognized. However, little is known about their function and phenotype in the inflammatory tumor microenvironment. Using a syngeneic, immunogenic model of colorectal cancer, we showed that TNFα-initiated inflammatory signaling in CT26 colorectal cancer cells selectively induced PD-L1 expression in stromal cells. Using CD274 shRNA and antibody-mediated approaches, we showed that stromal cell PD-L1 potentiated enhanced immunosuppression, characterized by inhibition of activated CD8+ granzyme B-secreting T cells in vitro, and the inhibition of CD8+ effector cells was associated with enhanced tumor progression. Stromal cell immunosuppressive and tumor-promoting effects could be reversed with administration of anti-PD-1 in vivo We validated our findings of stromal cell CD274 expression in two cohorts of clinical samples and also observed PD-L1 induction on human stromal cells in response to exposure to the inflammatory secretome from human colon cancer cells, irrespective of microsatellite instability. Collectively, our data showed that tumor-associated stromal cells support T-cell suppression by PD-L1 induction, which is dependent on colon cancer inflammatory signaling. Our findings reveal a key role of mesenchymal stromal cells PD-L1 in suppression of CD8+ antitumor immune responses and potentiation of colorectal cancer progression. Cancer Immunol Res; 6(11); 1426-41. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30228206     DOI: 10.1158/2326-6066.CIR-17-0443

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  33 in total

1.  Novel PD-L1 mAb HC16 reveals upregulation of PD-L1 in BAC subtype.

Authors:  Bor-Chyuan Su; Chen-Hung Ting; Kang-Yun Lee; Sheng-Ming Wu; Po-Hao Feng; Yao-Fei Chan; Jyh-Yih Chen
Journal:  Histol Histopathol       Date:  2020-10-28       Impact factor: 2.303

2.  Construction of an immune-related signature with prognostic value for colon cancer.

Authors:  Yunxia Lv; Xinyi Wang; Yu Ren; Xiaorui Fu; Taiyuan Li; Qunguang Jiang
Journal:  PeerJ       Date:  2021-05-05       Impact factor: 2.984

Review 3.  Modeling immune cell behavior across scales in cancer.

Authors:  Sahak Z Makaryan; Colin G Cess; Stacey D Finley
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2020-03-04

Review 4.  The influence of microenvironment on tumor immunotherapy.

Authors:  Jieying Zhang; Zhaopeng Shi; Xiang Xu; Zuoren Yu; Jun Mi
Journal:  FEBS J       Date:  2019-08-22       Impact factor: 5.542

Review 5.  Modifying the tumour microenvironment and reverting tumour cells: New strategies for treating malignant tumours.

Authors:  Ya Qi Cheng; Shou Bi Wang; Jia Hui Liu; Lin Jin; Ying Liu; Chao Yang Li; Ya Ru Su; Yu Run Liu; Xuan Sang; Qi Wan; Chang Liu; Liu Yang; Zhi Chong Wang
Journal:  Cell Prolif       Date:  2020-06-26       Impact factor: 6.831

6.  Stromal Score-Based Gene Signature: A Prognostic Prediction Model for Colon Cancer.

Authors:  Jing Jia; Yuhan Dai; Qing Zhang; Peiyu Tang; Qiang Fu; Guanying Xiong
Journal:  Front Genet       Date:  2021-05-12       Impact factor: 4.599

7.  The Enhanced Inhibitory Effect of Estrogen on PD-L1 Expression Following Nrf2 Deficiency in the AOM/DSS Model of Colitis-Associated Cancer.

Authors:  Changhee Kang; Chin-Hee Song; Nayoung Kim; Ryoung Hee Nam; Soo In Choi; Jeong Eun Yu; Heewon Nho; Jin A Choi; Jin Won Kim; Hee Young Na; Ha-Na Lee; Young-Joon Surh
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

8.  Development and validation of a five-immune gene prognostic risk model in colon cancer.

Authors:  Haitao Chen; Jun Luo; Jianchun Guo
Journal:  BMC Cancer       Date:  2020-05-06       Impact factor: 4.430

9.  TGF-β1-Licensed Murine MSCs Show Superior Therapeutic Efficacy in Modulating Corneal Allograft Immune Rejection In Vivo.

Authors:  Kevin Lynch; Oliver Treacy; Xizhe Chen; Nick Murphy; Paul Lohan; Md Nahidul Islam; Ellen Donohoe; Matthew D Griffin; Luke Watson; Steven McLoughlin; Grace O'Malley; Aideen E Ryan; Thomas Ritter
Journal:  Mol Ther       Date:  2020-05-30       Impact factor: 11.454

Review 10.  Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations.

Authors:  Qi Zhang; Yiwen Chen; Xueli Bai; Tingbo Liang
Journal:  Front Oncol       Date:  2020-10-15       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.